1.630CADMkt Cap: 124.50M CADP/E: —Last update: 2026-05-22
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) th…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap124.50M CAD
Enterprise Value122.53M CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.20M CAD
Revenue/Share—
Last Price1.630 CAD
Fiscal Year EndJul 2025
MR QuarterJan 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.55
PEG—
EV/EBITDA-29.79
EV/Revenue—
P/S—
P/B7.96
EPS (TTM)-0.06
EPS (Forward)-0.11
52W Range
—
52W High1.630 CAD
52W Low1.630 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.70%
ROA-24.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.22M CAD
CapEx (TTM)14.00K CAD
FCF Margin—
FCF Yield-0.36%
Net Debt329.00K CAD
Net Debt/EBITDA-0.08
Balance Sheet
Debt/Equity2.34
Current Ratio0.04
Quick Ratio0.02
Book Value/Sh0.2010 CAD
Cash/Share0.0000 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateAug 16, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.76.38M
Float54.27M
Insiders28.95%
Institutions0.00%
Short Interest
Short Ratio0.9d
Short % Float0.00%
Short % Out.0.00%
Shares Short2.68K
Short (prev mo.)1.49K
Technical
SMA 501.827 (-10.8%)
SMA 2001.978 (-17.6%)
Beta-0.31
S&P 52W Chg28.31%
Avg Vol (30d)200
Avg Vol (10d)2.81K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—